Cell and gene therapy specialist ElevateBio has taken the total fundraising since it launched five years ago to around $1.25 billion, with its latest $401 million round th
Boundless Bio’s plans to develop a new class of cancer therapies targeting DNA found outside the nucleus of malignant cells have been boosted by a $100 million fundraising
Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion
The first quarter of 2023 saw just £295 million raised by UK-based life sciences and biotech companies, signalling that investor confidence remains low after a disappointi
UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing